Traws Pharma (TRAW) AI Stock Analysis

• Market Cap: $10.15M
• Dividend Yield: N/A
• Average Volume (3M): 99.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: N/A
• EPS Growth: -404.67%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): 101.35
• Shares Outstanding: 5,073,790
• 10 Day Avg. Volume: 48,705
• 30 Day Avg. Volume: 99,153
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 38.02
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 313.79% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

Traws Pharma's overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.

Traws Pharma Business Overview & Revenue Model

Company Description

Traws Pharma (TRAW) is a biotechnology company specializing in the development and commercialization of innovative therapeutics. Operating within the pharmaceutical sector, Traws Pharma focuses on addressing unmet medical needs in areas such as oncology, neurology, and infectious diseases. The company is committed to advancing healthcare through cutting-edge research and development, leveraging both proprietary platforms and strategic collaborations to bring new treatments to market.

How the Company Makes Money

Traws Pharma generates revenue primarily through the sale of its pharmaceutical products and therapies that have gained regulatory approval. The company also engages in licensing agreements, where it grants other pharmaceutical firms access to its proprietary technologies and compounds in exchange for upfront payments, milestone fees, and royalties on sales. Additionally, Traws Pharma may receive funding from research grants and collaborations with academic institutions or other industry players. Strategic partnerships with larger pharmaceutical companies also contribute to its earnings, facilitating the co-development and co-promotion of new therapies.

Traws Pharma Financial Statement Overview

Summary

Traws Pharma faces significant financial challenges with minimal revenue growth, persistent operating losses, and negative equity. Despite a high gross profit margin, the negative cash flows and equity signal operational and solvency concerns. The lack of debt provides some financial flexibility, but urgent action is needed to ensure long-term sustainability.

Income Statement

Traws Pharma has consistently generated minimal revenue over the years, with no growth in total revenue from 2019 to the latest TTM period. The company is operating at a loss, with negative net income and EBIT margins, indicating profitability challenges. The gross profit margin is high due to low cost of goods sold relative to revenue, but the overall financial health is concerning due to substantial operating losses.

Balance Sheet

The company's balance sheet shows a troubling trend with negative stockholders' equity in the latest TTM period, indicating potential solvency issues. The absence of debt is a positive, as it reduces financial risk, but the negative equity ratio and declining assets are worrisome. Return on equity is negative, reflecting continuous losses impacting shareholders' value.

Cash Flow

Cash flow analysis reveals persistent negative operating cash flow, indicating operational inefficiencies. Free cash flow has also been negative, suggesting challenges in generating cash from operations after capital expenditures. The operating cash flow to net income ratio is negative, highlighting issues in cash conversion efficiency.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
226.00K	226.00K	226.00K	226.00K	231.00K	2.18M
	Gross Profit
214.00K	210.00K	212.00K	212.00K	231.00K	2.18M
	EBIT
-24.09M	-20.30M	-19.63M	-16.50M	-24.99M	-21.70M
	EBITDA
-24.08M	-20.28M	-19.61M	-16.48M	-24.98M	-21.68M
	Net Income Common Stockholders
-140.78M	-18.95M	-18.96M	-16.16M	-25.16M	-21.50M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
67.31M	20.82M	38.76M	55.07M	19.02M	22.73M
	Total Assets
70.76M	22.68M	39.37M	55.48M	19.99M	23.67M
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-67.31M	-20.82M	-38.76M	-55.07M	-19.02M	-22.73M
	Total Liabilities
42.54M	12.01M	11.06M	9.36M	13.81M	12.10M
	Stockholders Equity
28.21M	10.67M	28.31M	46.12M	6.17M	11.57M
Cash Flow		Free Cash Flow
-30.18M	-17.95M	-16.29M	-19.49M	-23.09M	-20.89M
	Operating Cash Flow
-30.18M	-17.93M	-16.29M	-19.49M	-23.07M	-20.83M
	Investing Cash Flow
-3.65M	-14.00K	0.00	0.00	-15.00K	-55.00K
	Financing Cash Flow
14.00M	0.00	0.00	55.56M	19.36M	26.65M

Traws Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAW, the sentiment is Negative. The current price of 1.45 is below the 20-day moving average (MA) of 2.09, below the 50-day MA of 3.12, and below the 200-day MA of 6.25, indicating a bearish trend. The MACD of -0.38 indicates Negative momentum. The RSI at 29.25 is Positive, neither overbought nor oversold. The STOCH value of 33.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRAW.

Traws Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
ADXN	45 Neutral	$11.36M	0.99	-85.36%	―	-70.05%	―
AFMD	42 Neutral	$11.25M	―	-151.46%	―	-95.23%	-325.89%
PSTV	38 Underperform	$10.90M	―	249.03%	―	18.54%	50.37%
RLYB	35 Underperform	$10.42M	―	-68.85%	―	―	27.35%
IBIO	29 Underperform	$6.91M	―	-123.28%	―	650.00%	89.72%
TRAW	28 Underperform	$10.15M	―	-2255.45%	―	―	-404.67%

Traws Pharma Corporate Events

Traws Pharma Appoints New Chairman Amid Leadership Changes

Traws Pharma, Inc. announced the appointment of Iain Dukes as the Interim Chief Executive Officer effective March 31, 2025, with an employment agreement effective April 1, 2025. This agreement outlines a one-year term, renewable annually, and includes a base salary of $610,000 with eligibility for an annual bonus. The agreement also specifies severance terms and benefits in case of termination. Additionally, on April 15, 2025, Dr. Dukes stepped down as Chairman of the Board, with Jack Stover appointed as the new Chairman, while Dr. Dukes remains a board member.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.

Traws Pharma’s overall stock score reflects significant financial challenges, including persistent losses and reliance on external financing. The technical analysis indicates a bearish trend, and the valuation shows a negative P/E ratio, further emphasizing the company’s financial difficulties. Despite some positive corporate events, such as securing financing and progress in investigational programs, these are insufficient to offset the broader financial struggles.

To see Spark’s full report on TRAW stock, click here.

Traws Pharma Reports 2024 Financial Results and CEO Change

On March 31, 2025, Traws Pharma announced its financial results for the year ending December 31, 2024, and highlighted significant progress in its investigational programs. The company reported positive data for its lead product candidate, tivoxavir marboxil, in treating bird flu, and ongoing FDA interactions for potential accelerated approval. Additionally, Traws Pharma completed a successful financing round, securing $20 million to support operations into Q1 2026. The company also announced the retirement of its CEO, Werner Cautreels, with Iain D. Dukes stepping in as Interim CEO.

Traws Pharma Announces CEO Transition and Investor Update

On March 28, 2025, Traws Pharma announced the retirement of CEO Werner Cautreels, effective March 31, 2025, with Iain D. Dukes stepping in as Interim CEO. Dr. Cautreels will remain on the Board and transition to a consulting role, while Dr. Dukes, with extensive leadership experience, will continue as Chairman. The company is advancing its antiviral programs for bird flu and COVID-19, with an investor update scheduled for March 31, 2025.

Traws Pharma Regains Nasdaq Compliance with $20M Financing

Traws Pharma announced on February 28, 2025, that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, ensuring continued listing on the Nasdaq Capital Market. This follows a successful hearing and a $20 million financing, positioning Traws to advance its antiviral programs, particularly for bird flu and influenza, while being subject to a one-year monitoring period to maintain compliance.